Goldman Sachs’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.48M | Buy |
626,787
+328,392
| +110% | +$4.44M | ﹤0.01% | 2387 |
|
|
2025
Q1 | $4.74M | Buy |
298,395
+186,480
| +167% | +$2.96M | ﹤0.01% | 2792 |
|
|
2024
Q4 | $1.38M | Buy |
111,915
+22,464
| +25% | +$277K | ﹤0.01% | 3717 |
|
|
2024
Q3 | $1.08M | Buy |
89,451
+32,628
| +57% | +$395K | ﹤0.01% | 3710 |
|
|
2024
Q2 | $665K | Buy |
56,823
+7,532
| +15% | +$88.1K | ﹤0.01% | 3806 |
|
|
2024
Q1 | $636K | Buy |
49,291
+3,706
| +8% | +$47.8K | ﹤0.01% | 3865 |
|
|
2023
Q4 | $392K | Buy |
+45,585
| New | +$392K | ﹤0.01% | 4063 |
|
|
2023
Q3 | – | Sell |
-16,326
| Closed | -$278K | – | 4859 |
|
|
2023
Q2 | $278K | Sell |
16,326
-11,439
| -41% | -$195K | ﹤0.01% | 4267 |
|
|
2023
Q1 | $435K | Buy |
+27,765
| New | +$435K | ﹤0.01% | 4144 |
|